Comparison of laboratory findings in the patients with MOG-ON and AQP4-ON
| MOG-ON | AQP4-ON | P value | |
| Number of patients, n | 20 | 45 | |
| Coexisting autoimmunity, no. (%) | 0/20, 0 | 19/45, 42.2 | 0.001* |
| ANA | 0/20, 0 | 16/45, 35.6 | 0.006* |
| Anti-SSA | 0/20, 0 | 10/45, 22.2 | 0.055* |
| Anti-SSB | 0/20, 0 | 4/45, 8.9 | 0.414* |
| HLA-B27 | 0/20, 0 | 4/45, 8.9 | 0.414* |
| Thyroperoxidase and thyroglobulin antibodies | 0/20, 0 | 3/45, 6.7 | 0.547† |
| CSF analysis | |||
| White cell count elevated | 1/20, 5 | 5/45, 11.1 | 0.748* |
| Protein elevated | 0/20, 0 | 3/45, 6.7 | 0.547† |
| IgG level elevated | 0/20, 0 | 2/45, 4.4 | >0.999† |
| OCB positive | 1/20, 5 | 0/45, 0 | 0.308† |
*Pearson χ2 test.
†Fisher’s exact test.
‡Independent t-test.
ANA, antinuclear antibodies; anti-SSA, anti-Sjögren syndrome A antibodies; anti-SSB, anti-Sjögren syndrome B antibodies; AQP4-ON, aquaporin-4 antibody-associated ON; CSF, cerebrospinal fluid; HLA-B27, histocompatibility complex-B27; MOG-ON, myelin oligodendrocyte glycoprotein antibody-associated ON; OCB, oligoclonal band; ON, optic neuritis.